hy said on the 9th that it confirmed the stomach mucosal protection and anti-inflammatory effects of its patented probiotic "HP7 (Lacticaseibacillus paracasei HP7)" and published the related paper in the international journal Journal of Medicinal Food.
HP7 is a Korea-type probiotic isolated from kimchi. It is a key strain independently developed by hy and applied to the company's major brands.
The study was conducted jointly with a research team led by Professor Lee Yu-hyeon of the Department of Food and Nutrition at Suwon University and identified HP7's stomach mucosal protection and anti-inflammatory effects in a Helicobacter pylori (Helicobacter pylori) infection environment.
Regarding the results, Lee said, "What is notable is that HP7 demonstrated the same level of anti-inflammatory and stomach mucosal protection effects not only in its live form but also in its postbiotics form," adding, "Regardless of survival, it is meaningful in that it scientifically supports the inherent functionality of the bacterial cell components themselves."
The researchers applied HP7 in both live and postbiotics forms to compare effects. Postbiotics are inactivated cells or derived components produced by heat treatment and other methods, offering high stability and suitability for use in various formulations.
Across all experimental subjects, the results showed: ▲ reduced blood indicators of Helicobacter pylori infection ▲ reductions in six inflammatory cytokines ▲ mitigation of stomach tissue damage. In addition, a stomach mucosal protection effect was observed.
An hy official said, "Through this paper, we confirmed the potential to use HP7 as postbiotics," adding, "We will continue to lead next-generation biotics based on research into our proprietary strains."